Systematic substrate identification indicates a central role for the metalloprotease ADAM10 in axon targeting and synapse function

  1. Peer-Hendrik Kuhn  Is a corresponding author
  2. Alessio Vittorio Colombo
  3. Benjamin Schusser
  4. Daniela Dreymueller
  5. Sebastian Wetzel
  6. Ute Schepers
  7. Julia Herber
  8. Andreas Ludwig
  9. Elisabeth Kremmer
  10. Dirk Montag
  11. Ulrike Müller
  12. Michaela Schweizer
  13. Paul Saftig
  14. Stefan Bräse
  15. Stefan F Lichtenthaler
  1. Technische Universität München, Germany
  2. Ludwig-Maximilians-Universität München, Germany
  3. Uniklinik RWTH Aachen, Germany
  4. Christian-Albrechts Universität zu Kiel, Germany
  5. Karlsruhe Institute of Technology, Germany
  6. Helmholtz Zentrum München, Germany
  7. Leibniz Institute for Neurobiology, Germany
  8. Heidelberg University, Germany
  9. Zentrum für Molekulare Neurobiologie, Germany

Abstract

Metzincin metalloproteases have major roles in intercellular communication by modulating the function of membrane proteins. One of the proteases is the a-disintegrin-and-metalloprotease 10 (ADAM10) which acts as alpha-secretase of the Alzheimer's disease amyloid precursor protein. ADAM10 is also required for neuronal network functions in murine brain, but neuronal ADAM10 substrates are only partly known. With a proteomic analysis of Adam10-deficient neurons we identified 91, mostly novel ADAM10 substrate candidates, making ADAM10 a major protease for membrane proteins in the nervous system. Several novel substrates, including the neuronal cell adhesion protein NrCAM, are involved in brain development. Indeed, we detected mistargeted axons in the olfactory bulb of conditional ADAM10-/- mice, which correlate with reduced cleavage of NrCAM, NCAM and other ADAM10 substrates. In summary, the novel ADAM10 substrates provide a molecular basis for neuronal network dysfunctions in conditional ADAM10-/- mice and demonstrate a fundamental function of ADAM10 in the brain.

Article and author information

Author details

  1. Peer-Hendrik Kuhn

    Neuroproteomics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
    For correspondence
    peerhendrik@gmx.net
    Competing interests
    The authors declare that no competing interests exist.
  2. Alessio Vittorio Colombo

    Neuroproteomics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Benjamin Schusser

    Department of Animal Science, Institute for Animal Physiology, Ludwig-Maximilians-Universität München, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Daniela Dreymueller

    Institute of Pharmacology and Toxicology, Uniklinik RWTH Aachen, Aachen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Sebastian Wetzel

    Institute of Biochemistry, Christian-Albrechts Universität zu Kiel, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Ute Schepers

    Karlsruhe Institute of Technology, Karlsruhe, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Julia Herber

    Neuroproteomics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Andreas Ludwig

    Institute for Pharmacology and Toxicology, Uniklinik RWTH Aachen, Aachen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Elisabeth Kremmer

    German Research Center for Environmental Health, Institute of Molecular Tumor immunology, Helmholtz Zentrum München, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Dirk Montag

    Neurogenetics, Leibniz Institute for Neurobiology, Magdeburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  11. Ulrike Müller

    Department of Functional Genomics, Institute for Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Michaela Schweizer

    Service-Gruppe für Elektronenmikroskopie, Zentrum für Molekulare Neurobiologie, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  13. Paul Saftig

    Institute of Biochemistry, Christian-Albrechts Universität zu Kiel, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.
  14. Stefan Bräse

    Karlsruhe Institute of Technology, Karlsruhe, Germany
    Competing interests
    The authors declare that no competing interests exist.
  15. Stefan F Lichtenthaler

    Neuroproteomics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Bart De Strooper, VIB Center for the Biology of Disease, KU Leuven, Belgium

Version history

  1. Received: November 2, 2015
  2. Accepted: January 22, 2016
  3. Accepted Manuscript published: January 23, 2016 (version 1)
  4. Version of Record published: February 26, 2016 (version 2)

Copyright

© 2016, Kuhn et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,187
    views
  • 1,207
    downloads
  • 124
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Peer-Hendrik Kuhn
  2. Alessio Vittorio Colombo
  3. Benjamin Schusser
  4. Daniela Dreymueller
  5. Sebastian Wetzel
  6. Ute Schepers
  7. Julia Herber
  8. Andreas Ludwig
  9. Elisabeth Kremmer
  10. Dirk Montag
  11. Ulrike Müller
  12. Michaela Schweizer
  13. Paul Saftig
  14. Stefan Bräse
  15. Stefan F Lichtenthaler
(2016)
Systematic substrate identification indicates a central role for the metalloprotease ADAM10 in axon targeting and synapse function
eLife 5:e12748.
https://doi.org/10.7554/eLife.12748

Share this article

https://doi.org/10.7554/eLife.12748

Further reading

    1. Cancer Biology
    2. Cell Biology
    Dongyue Jiao, Huiru Sun ... Kun Gao
    Research Article

    Enhanced protein synthesis is a crucial molecular mechanism that allows cancer cells to survive, proliferate, metastasize, and develop resistance to anti-cancer treatments, and often arises as a consequence of increased signaling flux channeled to mRNA-bearing eukaryotic initiation factor 4F (eIF4F). However, the post-translational regulation of eIF4A1, an ATP-dependent RNA helicase and subunit of the eIF4F complex, is still poorly understood. Here, we demonstrate that IBTK, a substrate-binding adaptor of the Cullin 3-RING ubiquitin ligase (CRL3) complex, interacts with eIF4A1. The non-degradative ubiquitination of eIF4A1 catalyzed by the CRL3IBTK complex promotes cap-dependent translational initiation, nascent protein synthesis, oncogene expression, and cervical tumor cell growth both in vivo and in vitro. Moreover, we show that mTORC1 and S6K1, two key regulators of protein synthesis, directly phosphorylate IBTK to augment eIF4A1 ubiquitination and sustained oncogenic translation. This link between the CRL3IBTK complex and the mTORC1/S6K1 signaling pathway, which is frequently dysregulated in cancer, represents a promising target for anti-cancer therapies.

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Natalia Dolgova, Eva-Maria E Uhlemann ... Oleg Y Dmitriev
    Research Article Updated

    Mediator of ERBB2-driven cell motility 1 (MEMO1) is an evolutionary conserved protein implicated in many biological processes; however, its primary molecular function remains unknown. Importantly, MEMO1 is overexpressed in many types of cancer and was shown to modulate breast cancer metastasis through altered cell motility. To better understand the function of MEMO1 in cancer cells, we analyzed genetic interactions of MEMO1 using gene essentiality data from 1028 cancer cell lines and found multiple iron-related genes exhibiting genetic relationships with MEMO1. We experimentally confirmed several interactions between MEMO1 and iron-related proteins in living cells, most notably, transferrin receptor 2 (TFR2), mitoferrin-2 (SLC25A28), and the global iron response regulator IRP1 (ACO1). These interactions indicate that cells with high-MEMO1 expression levels are hypersensitive to the disruptions in iron distribution. Our data also indicate that MEMO1 is involved in ferroptosis and is linked to iron supply to mitochondria. We have found that purified MEMO1 binds iron with high affinity under redox conditions mimicking intracellular environment and solved MEMO1 structures in complex with iron and copper. Our work reveals that the iron coordination mode in MEMO1 is very similar to that of iron-containing extradiol dioxygenases, which also display a similar structural fold. We conclude that MEMO1 is an iron-binding protein that modulates iron homeostasis in cancer cells.